JP2017513836A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513836A5
JP2017513836A5 JP2016561799A JP2016561799A JP2017513836A5 JP 2017513836 A5 JP2017513836 A5 JP 2017513836A5 JP 2016561799 A JP2016561799 A JP 2016561799A JP 2016561799 A JP2016561799 A JP 2016561799A JP 2017513836 A5 JP2017513836 A5 JP 2017513836A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
methylphenoxy
thio
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561799A
Other languages
English (en)
Japanese (ja)
Other versions
JP6865038B2 (ja
JP2017513836A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/025416 external-priority patent/WO2015157697A1/en
Publication of JP2017513836A publication Critical patent/JP2017513836A/ja
Publication of JP2017513836A5 publication Critical patent/JP2017513836A5/ja
Application granted granted Critical
Publication of JP6865038B2 publication Critical patent/JP6865038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561799A 2014-04-11 2015-04-10 Ｎａｆｌｄおよびｎａｓｈの治療 Active JP6865038B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11
US61/978,335 2014-04-11
PCT/US2015/025416 WO2015157697A1 (en) 2014-04-11 2015-04-10 Treatment of nafld and nash

Publications (3)

Publication Number Publication Date
JP2017513836A JP2017513836A (ja) 2017-06-01
JP2017513836A5 true JP2017513836A5 (index.php) 2018-05-24
JP6865038B2 JP6865038B2 (ja) 2021-04-28

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561799A Active JP6865038B2 (ja) 2014-04-11 2015-04-10 Ｎａｆｌｄおよびｎａｓｈの治療

Country Status (27)

Country Link
US (7) US9381181B2 (index.php)
EP (1) EP3129018B1 (index.php)
JP (1) JP6865038B2 (index.php)
KR (1) KR102374499B1 (index.php)
CN (1) CN106163508A (index.php)
AU (1) AU2015243239B2 (index.php)
BR (1) BR112016023269A8 (index.php)
CA (1) CA2944139C (index.php)
CL (1) CL2016002517A1 (index.php)
CY (1) CY1122602T1 (index.php)
DK (1) DK3129018T3 (index.php)
EA (1) EA036704B1 (index.php)
ES (1) ES2764467T3 (index.php)
HR (1) HRP20192299T1 (index.php)
IL (1) IL248193B (index.php)
LT (1) LT3129018T (index.php)
MX (1) MX369921B (index.php)
NZ (1) NZ724740A (index.php)
PH (1) PH12016501978B1 (index.php)
PL (1) PL3129018T3 (index.php)
PT (1) PT3129018T (index.php)
RS (1) RS59637B1 (index.php)
SG (1) SG11201608077PA (index.php)
SI (1) SI3129018T1 (index.php)
SM (1) SMT202000019T1 (index.php)
UA (1) UA121208C2 (index.php)
WO (1) WO2015157697A1 (index.php)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2632967T3 (es) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010241571B2 (en) 2009-04-29 2014-06-26 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
EA039108B1 (ru) 2012-06-29 2021-12-06 Амарин Фармасьютикалз Айрлэнд Лимитед Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
DK3119384T3 (en) 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP6865038B2 (ja) 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
SG11201609953XA (en) 2014-05-28 2016-12-29 Childrens Hosp Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
WO2016154258A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049157A1 (en) * 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
KR20240164965A (ko) * 2016-11-04 2024-11-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
EP4234536A3 (en) 2017-05-05 2023-10-25 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3681537A1 (en) 2017-09-13 2020-07-22 Novartis AG Combinations comprising fxr agonists
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
US11260066B2 (en) 2017-10-27 2022-03-01 Samyang Corporation Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
MX2020005621A (es) 2017-12-06 2020-08-20 Basf As Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
SI4056176T1 (sl) 2018-09-24 2024-09-30 Amarin Pharmaceuticals Ireland Limited Metode zmanjševanja tveganja za kardiovaskularne dogodke pri subjektu
SG11202104951RA (en) * 2018-11-16 2021-06-29 Cymabay Therapeutics Inc Combination treatment of nafld and nash
WO2020102351A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
JP2022534398A (ja) 2019-05-31 2022-07-29 チルドレンズ ホスピタル メディカル センター 形成オルガノイド組成物およびその作製方法
WO2021041237A1 (en) 2019-08-23 2021-03-04 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
JP2023525571A (ja) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の併用処置
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238445A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
TR199801581T2 (xx) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
UA87467C2 (en) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
DK3119384T3 (en) 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
JP6865038B2 (ja) * 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
AU2015279905A1 (en) 2014-06-26 2017-02-02 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia

Similar Documents

Publication Publication Date Title
JP2017513836A5 (index.php)
JP2017505285A5 (index.php)
HRP20192299T1 (hr) Liječenje nafld i nash
JP2017508817A5 (index.php)
JP2016511753A5 (index.php)
JP2011201907A5 (index.php)
JP2017537066A5 (index.php)
JP2015512931A5 (index.php)
JP2014515013A5 (index.php)
JP2016510326A5 (index.php)
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
JP2015078230A5 (index.php)
JP2014507446A5 (index.php)
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2018507914A5 (index.php)
JP2009530398A5 (index.php)
JP2017520613A5 (index.php)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2017517565A5 (index.php)
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
JP2016535082A5 (index.php)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
JP2011046708A5 (index.php)
JP2015516419A5 (index.php)
JP2017519028A5 (index.php)